Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Eledon Pharmaceuticals, Inc. | nvus-ex322_7.htm |
| EX-31.2 - EX-31.2 - Eledon Pharmaceuticals, Inc. | nvus-ex312_9.htm |
| EX-31.1 - EX-31.1 - Eledon Pharmaceuticals, Inc. | nvus-ex311_6.htm |
| 10-Q - 10-Q - Eledon Pharmaceuticals, Inc. | nvus-10q_20200930.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Novus Therapeutics, Inc. (the “Company”) for the period ended September 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, David-Alexandre C. Gros, Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
(1) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of
1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
Date: November 16, 2020 |
|
By: |
|
/s/ David-Alexandre C. Gros, M.D. |
|
|
|
|
|
David-Alexandre C. Gros |
|
|
|
|
|
Chief Executive Officer (Principal Executive Officer) |